{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:52:14Z","timestamp":1780120334359,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Singapore-MIT Alliance"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1002\/jps.24520","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T14:36:05Z","timestamp":1434724565000},"page":"2433-2440","source":"Crossref","is-referenced-by-count":40,"title":["Rational Design of Biobetters with Enhanced Stability"],"prefix":"10.1016","volume":"104","author":[{"given":"Fabienne","family":"Courtois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtiss P.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj J.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt L.","family":"Trout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24520_bb0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nbt.2794","article-title":"What's fueling the biotech engine\u20142012 to 2013","volume":"32","author":"Aggarwal","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1002\/jps.24520_bb0010","author":"Rader"},{"key":"10.1002\/jps.24520_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/mabs.3.2.14785","article-title":"Biosimilar, biobetter and next generation therapeutic antibodies","volume":"3","author":"Beck","year":"2011","journal-title":"mAbs"},{"key":"10.1002\/jps.24520_bb0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: An immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"key":"10.1002\/jps.24520_bb0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11095-011-0414-9","article-title":"Coupling of aggregation and immunogenicity in biotherapeutics: T- and B cell immune epitopes may contain aggregation prone regions","volume":"28","author":"Kumar","year":"2011","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24520_bb0030","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11095-010-0297-1","article-title":"Strategies for the assessment of protein aggregates in pharmaceutical biotech product development","volume":"28","author":"den Engelsman","year":"2001","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24520_bb0035","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)"},{"key":"10.1002\/jps.24520_bb0040","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1073\/pnas.0904191106","article-title":"Design of therapeutic proteins with enhanced stability","volume":"106","author":"Chennamsetty","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.24520_bb0045","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmb.2009.06.028","article-title":"Aggregation-prone motifs in human immunoglobulin G","volume":"391","author":"Chennamsetty","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1002\/jps.24520_bb0050","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4161\/mabs.1.6.9773","article-title":"Predictive tools for stabilization of therapeutic proteins","volume":"1","author":"Voynov","year":"2009","journal-title":"mAbs"},{"key":"10.1002\/jps.24520_bb0055","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.1002\/jps.24520_bb0060","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJM200410283511820","article-title":"Rituximab for rheumatoid arthritis","volume":"351","author":"Okamoto","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.24520_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/1744666X.3.1.17","article-title":"Rituximab in the treatment of rheumatoid arthritis","volume":"3","author":"Taylor","year":"2007","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1002\/jps.24520_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pro.309","article-title":"Aggregation of a multidomain protein: A coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress","volume":"19","author":"Andersen","year":"2010","journal-title":"Protein Sci"},{"key":"10.1002\/jps.24520_bb0075","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1074\/jbc.M701654200","article-title":"Structural basis for recognition of CD20 by therapeutic antibody rituximab","volume":"282","author":"Du","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.24520_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graph"},{"key":"10.1002\/jps.24520_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: An immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1002\/jps.24520_bb0090","series-title":"Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma","author":"Anderson","year":"1998"},{"key":"10.1002\/jps.24520_bb0095","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tibtech.2013.07.002","article-title":"Toward aggregation-resistant antibodies by design","volume":"31","author":"Lee","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1002\/jps.24520_bb0100","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/prot.22926","article-title":"Prediction of protein binding regions","volume":"79","author":"Chennamsetty","year":"2011","journal-title":"Proteins"},{"key":"10.1002\/jps.24520_bb0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"Consistent treatment of internal and surface residues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J Chem Theory Comput"},{"key":"10.1002\/jps.24520_bb0110","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1073\/pnas.1202866109","article-title":"General strategy for the generation of human antibody variable domains with increased aggregation resistance","volume":"109","author":"Dudgeon","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.24520_bb0115","first-page":"255","article-title":"Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression mAbs>","volume":"5","author":"Buchanan","year":"2013"},{"key":"10.1002\/jps.24520_bb0120","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1021\/jp911706q","article-title":"Prediction of aggregation prone regions of therapeutic proteins","volume":"114","author":"Chennamsetty","year":"2010","journal-title":"J Phys Chem B"},{"key":"10.1002\/jps.24520_bb0125","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma","volume":"10","author":"Stein","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1002\/jps.24520_bb0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4161\/mabs.27431","article-title":"High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy","volume":"6","author":"Liu","year":"2014","journal-title":"mAbs"},{"key":"10.1002\/jps.24520_bb0135","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1002\/jps.22705","article-title":"Aggregation in protein-based biotherapeutics: Computational studies and tools to identify aggregation prone regions","volume":"100","author":"Agrawal","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24520_bb0140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4161\/mabs.1.3.8035","article-title":"Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies","volume":"1","author":"Wang","year":"2009","journal-title":"mAbs"},{"key":"10.1002\/jps.24520_bb0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jps.22758","article-title":"Developability index: A rapid in silico tool for the screening of antibody aggregation propensity","volume":"101","author":"Lauer","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24520_bb0150","series-title":"Her2-and vegf-a-binding proteins with enhanced stability","author":"Trout","year":"2013"},{"key":"10.1002\/jps.24520_bb0155","series-title":"Cd20-and egfr-binding proteins enhanced stability","author":"Trout","year":"2013"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915300174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915300174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T21:36:29Z","timestamp":1599168989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915300174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0022354915300174"],"URL":"https:\/\/doi.org\/10.1002\/jps.24520","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}